Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;28(2):141-6.
doi: 10.1002/jcla.21658. Epub 2014 Jan 6.

The effect of paraprotein on platelet aggregation

Irena Djunic  1 , Ivo Elezovic, Vesna Ilic, Nadezda Milosevic-Jovcic, Jelena Bila, Nada Suvajdzic-Vukovic, Darko Antic, Ana Vidovic, Dragica Tomin
Affiliations

The effect of paraprotein on platelet aggregation

Irena Djunic et al. J Clin Lab Anal. 2014 Mar.

Abstract

Background: Some patients with paraproteinemia have platelet aggregation disorders and the aim of this study was to examine disturbance of platelet aggregation in healthy blood donors by isolated paraprotein in vitro.

Methods: Using Rivanol, paraprotein was separated from the serum of ten patients with paraproteinemia, who had decreased platelet aggregation with several inducers. Platelet aggregation in ten healthy donors was measured with and without addition of the isolated induced paraprotein. The test was repeated with added human immunoglobulins for intravenous use.

Results: Average of maximal levels of platelet aggregation has been significantly decreased in plasma rich in platelets (PRP) of healthy donors after addition of paraprotein when inducers are used: adenosine diphosphate (ADP) (P = 0.007), collagen (COL) (P = 0.008), ristocetin (RIS) (P = 0.001), and epinephrine (EPI) (P = 0.002). Average of latent time of platelet aggregation was significantly prolonged in healthy donors after addition of paraprotein with inducers: COL (P = 0.008), RIS (P = 0.008) and EPI (P = 0.006) while addition of human immunoglobulins caused no change in platelet aggregation. In comparison, when human immunoglobulins were added, maximal platelet aggregation and latent time did not change significantly. Paraprotein isolated from patients with paraproteinamia, who had decrease platelet aggregation, had significantly decreased platelet aggregation when added to PRP of healthy donors, in vitro.

Conclusion: Platelet aggregation was not significantly changed was confirmed with addition of human immunoglobulins.

Keywords: paraproteinemia; platelet aggregation; role of paraprotein.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Figure 1
Figure 1
Platelet aggregation by ADP in PRP of healthy donors before and after addition of paraprotein (P = 0.007).
Figure 2
Figure 2
Platelet aggregation by COL in PRP of healthy donors before and after addition of paraprotein (P = 0.002).
Figure 3
Figure 3
Platelet aggregation by RIS in PRP of healthy donors before and after addition of paraprotein (P = 0.001).
Figure 4
Figure 4
Platelet aggregation by EPI in PRP of healthy donors before and after addition of paraprotein (P = 0.002).
See this image and copyright information in PMC

References

    1. Apitz K. The disturbance of protein metabolism in plasmocytoma. Klin Wochenschr 1940;19:1058–1061.
    1. Riva G. The macroglobulinemia of Waldenstrom. Helv Med Acta 1958;25:1–2. - PubMed
    1. Kawai T. Plasma Protein Changes in M‐proteinemic Type In Kawai T. (Ed.). Clinical Aspects of Plasma Proteins, Heidelberg, Berlin and New York: Springer‐Verlag; 1973. p 305–373.
    1. Edelman GM. Dissociation of gamma globulins. J Am Chem Soc 1959;38:3155–3162.
    1. Porter PR. The hydrolysis of rabbit gamma globulin and antibodies with crystaline papain. Biochem J 1959;73:119–125. - PMC - PubMed